Advertisement

Mifepristone as a Psychopharmacologic Agent: Consideration of Efficacy, Plasma Levels, and Mechanism of Action

      SEE CORRESPONDING ARTICLE ON PAGE 46
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Block T.S.
        • Kushner H.
        • Kalin N.
        • Nelson C.
        • Belanoff J.
        • Schatzberg A.
        Combined analysis of mifepristone for psychotic depression: Plasma levels associated with clinical response.
        Biol Psychiatry. 2018; 84: 46-54
        • Sitruk-Ware R.
        • Spitz I.M.
        Pharmacological properties of mifepristone: Toxicology and safety in animal and human studies.
        Contraception. 2003; 68: 409-420
        • Heikinheimo O.
        • Lähteenmäki P.L.
        • Koivunen E.
        • Shoupe D.
        • Croxatto H.
        • Luukkainen T.
        • Lähteenmäki P.
        Metabolism and serum binding of RU 486 in women after various single doses.
        Hum Reprod. 1987; 2: 379-385
        • Bertagna X.
        • Bertagna C.
        • Luton J.P.
        • Husson J.M.
        • Girard F.
        The new steroid analog RU 486 inhibits glucocorticoid action in man.
        J Clin Endocrinol Metab. 1984; 59: 25-28
        • Belanoff J.K.
        • Rothschild A.J.
        • Cassidy F.
        • DeBattista C.
        • Baulieu E.E.
        • Schold C.
        • Schatzberg A.F.
        An open label trial of C-1073 (mifepristone) for psychotic major depression.
        Biol Psychiatry. 2002; 52: 386-392
        • Gallagher P.
        • Young A.H.
        Mifepristone (RU-486) treatment for depression and psychosis: A review of the therapeutic implications.
        Neuropsychiatr Dis Treat. 2006; 2: 33-42
        • Golier J.A.
        • Caramanica K.
        • Demaria R.
        • Yehuda R.
        A pilot study of mifepristone in combat-related PTSD.
        Depress Res Treat. 2012; 2012: 393251
        • Golier J.A.
        • Caramanica K.
        • Michaelides A.C.
        • Makotkine I.
        • Schmeidler J.
        • Harvey P.D.
        • Yehuda R.
        A randomized, double-blind, placebo-controlled, crossover trial of mifepristone in Gulf War veterans with chronic multisymptom illness.
        Psychoneuroendocrinology. 2016; 64: 22-30
        • Lenze E.J.
        • Hershey T.
        • Newcomer J.W.
        • Karp J.F.
        • Blumberger D.
        • Anger J.
        • Doré P.
        • Dixon D.
        Antiglucocorticoid therapy for older adults with anxiety and co-occurring cognitive dysfunction: results from a pilot study with mifepristone.
        Int J Geriatr Psychiatry. 2014; 29: 962-969
        • Vendruscolo L.F.
        • Estey D.
        • Goodell V.
        • Macshane L.G.
        • Logrip M.L.
        • Schlosburg J.E.
        • et al.
        Glucocorticoid receptor antagonism decreases alcohol seeking in alcohol-dependent individuals.
        J Clin Invest. 2015; 125: 3193-3197

      Linked Article

      • Combined Analysis of Mifepristone for Psychotic Depression: Plasma Levels Associated With Clinical Response
        Biological PsychiatryVol. 84Issue 1
        • Preview
          Patients with psychotic depression exhibit elevated cortisol levels. Competitively antagonizing cortisol at the glucocorticoid receptor with mifepristone demonstrated therapeutic benefit in early studies of patients with psychotic depression. We present a combined analysis of all controlled phase 2 and 3 studies to report antipsychotic differences between treatment with mifepristone or placebo and to evaluate the relative contributions to response of attaining an a priori–defined, high mifepristone plasma level and markers of glucocorticoid receptor antagonism (increases in adrenocorticotropin hormone and cortisol) with treatment.
        • Full-Text
        • PDF
        Open Access